The Interaction of MCI-154, a Calcium Sensitizer, and Isoflurane on Systemic and Coronary Hemodynamics in Chronically Instrumented Dogs

Anesthesia and Analgesia

Volumn 98, Issue 1, 2004, Pages 30-36

  Takahashi, Shunji ^a   Cho, Sungsam ^a   Hara, Tetsuya ^a   Ureshino, Hiroyuki ^a   Tomiyasu, Shiro ^a   Sumikawa, Koji ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4,5 DIHYDRO 6 [4 (4 PYRIDYLAMINO)PHENYL] 3(2H) PYRIDAZINONE; CALCIUM SENSITIZER; ISOFLURANE;

ANIMAL EXPERIMENT; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CARDIOVASCULAR EFFECT; CHRONICALLY INSTRUMENTED DOG; CONSCIOUSNESS; CORONARY ARTERY BLOOD FLOW; CORONARY HEMODYNAMICS; CORONARY VASCULAR RESISTANCE; DRUG POTENTIATION; EXPERIMENTAL ANIMAL; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE OXYGEN CONSUMPTION; HEART OUTPUT; HEART PRELOAD; HEART PRELOAD RECRUITABLE STROKE WORK; HEART RATE; INHALATION ANESTHESIA; MALE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRESSURE WORK INDEX; PRIORITY JOURNAL; RATE PRESSURE PRODUCT; SYSTEMIC CIRCULATION;

EID: 0347993875     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ANE.0000093248.50724.BE     Document Type: Article

References (28)

1. Narimatsu A, Kitada Y, Satoh N, et al. Cardiovascular pharmacology of 6-[4-(4′-pyridyl)aminophenyl]-4, 5-dihydro-3(2H)-pyridazinone hydrochloride, a novel and potent cardiotonic agent with vasodilator properties. Arzneimittelforschung 1987;37:398-406.
2. Kitada Y, Narimatsu A, Suzuki R, et al. Does the positive inotropic action of a novel cardiotonic agent, MCI-154, involve mechanisms other than cyclic AMP? J Pharmacol Exp Ther 1987;243:639-45.
3. ++ sensitivity of the contractile system by MCI-154, a novel cardiotonic agent, in chemically skinned fibers from the guinea pig papillary muscles. J Pharmacol Exp Ther 1987;243:633-8.
4. ++ binding by MCI-154, a novel cardiotonic agent. J Pharmacol Exp Ther 1989;250:272-7.
5. 2+ activation of skinned human myocardium. Eur J Pharmacol 1989;165:305-8.
6. 2+ sensitization with a new cardiotonic agent, MCI-154, on diseased human hearts. Cardiovasc Res 1995;30:915-22.
7. Abe Y, Kitada Y, Narimatsu A. Beneficial effect of MCI-154, a cardiotonic agent, on ischemic contractile failure and myocardial acidosis of dog hearts: comparison with dobutamine, milrinone and pimobendan. J Pharmacol Exp Ther 1992;261:1087-95.
8. Abe Y, Kitada Y, Narimatsu A. Effect of MCI-154, a cardiotonic agent, on regional contractile function and myocardial oxygen consumption in the presence and absence of coronary artery stenosis in dogs. J Pharmacol Exp Ther 1993;265:819-25.
9. Mori M, Takeuchi M, Takaoka H, et al. Oxygen-saving effect of a new cardiotonic agent, MCI-154, in diseased human hearts. J Am Coll Cardiol 1997;29:613-22.
10. 2+ sensitizer, MCI-154, on the myocardial oxygen consumption-cardiac output relation in patients with left ventricular dysfunction after myocardial infarction: comparison with dobutamine and phosphodiesterase inhibitor. Am Heart J 1997;133:283-9.
11. Teramura S, Yamakado T, Maeda M, Nakano T. Effects of MCI-154, a calcium sensitizer, on left ventricular systolic and diastolic function in pacing-induced heart failure in the dogs. Circulation 1997;95:732-9.
12. Al-Wathiqui MH, Shimshak TM, Brooks HL, et al. Comparative effects of inotropic agents on coronary and systemic hemodynamics of conscious dogs: actions of milrinone, dopamine, ouabain and MCI-154. Pharmacology 1988;36:217-27.
13. + channel of vascular smooth muscle cells. Life Sci 1995;56:291-8.
14. 2+ content, and twitch force in intact trabeculae. Am J Physiol 1998;275:H1360-9.
15. Buljubasic N, Rusch NJ, Marijic J, et al. Effect of halothane and isoflurane on calcium and potassium channel currents in canine coronary arterial cells. Anesthesiology 1992;76:990-8.
16. Crystal GJ, Gurevicius J, Salem MR, Zhou X. Role of adenosine triphosphate-sensitive potassium channels in coronary vasodilation by halothane, isoflurane, and enflurane. Anesthesiology 1997;86:448-58.
17. Pagel PS, Harkin CP, Hettrick DA, Warltier DC. Levosimendan (OR-1259), a myofilament calcium sensitizer, enhances myocardial contractility but does not alter isovolemic relaxation in conscious and anesthetized dogs. Anesthesiology 1994;81:974-87.
18. Rooke GA, Feigl EO. Work as correlate of canine left ventricular oxygen consumption, and the problem of catecholamine oxygen wasting. Circ Res 1982;50:273-86.
19. Schipke JD, Burkhoff D, Kass DA, et al. Hemodynamic dependence of myocardial oxygen indexes. Am J Physiol 1990;258: H1281-91.
20. 2+-sensitizer" MCI-154 in intact pigs. Scand Cardiovasc J 2002;36:172-9.
21. Pagel PS, Hettrick DA, Warltier DC. Amrinone enhances myocardial contractility and improves left ventricular diastolic function in conscious and anesthetized chronically instrumented dogs. Anesthesiology 1993;79:753-65.
22. Takaoka H, Takeuchi M, Odake M, et al. Comparison of the effects on arterial-ventricular coupling between phosphodiesterase inhibitor and dobutamine in the diseased human heart. Am Coll Cardiol 1993;22:598-606.
23. Hajjar RJ, Gwathmey JK. Calcium-sensitizing inotropic agents in the treatment of heart failure: a critical view. Cardiovasc Drugs Ther 1991;5:961-6.
24. Hgashiyama A, Watkins MW, Chen Z, et al. Effects of EMD 57033 on contraction and relaxation in isolated rabbit hearts. Circulation 1995;92:3094-104.
25. Hosono M, Taira N. Cardiac and coronary vasodilator effects of the novel cardiotonic agent, MCI-154, assessed in isolated, blood-perfused dog heart preparations. J Cardiovasc Pharmacol 1987;10:692-8.
26. 2+ sensitizers, on isolated, blood-perfused dog heart preparations. Jpn J Pharmacol 1998;76:435-9.
27. Bethke T, Meyer W, Schmitz W, et al. High selectivity for inhibition of phosphodiesterase III and positive inotropic effects of MCI-154 in guinea pig myocardium. J Cardiovasc Pharmacol 1993;21:847-55.
28. Verdouw PD, Hartog JM, Duncker DJ, et al. Cardiovascular profile of pimobendan, a benzimidazole-pyridazinone derivative with vasodilating and inotropic properties. Eur J Pharmacol 1986;126:21-30.